Objective:

To determine if modeling EEG spectral power changes according to distinct neurotransmitter systems enhances understanding of psychotropic drug effects.

Approach:

Key Findings:

• Dopamine antagonists associated with higher delta and theta power at central locations and lower alpha power at occipital and temporal locations.
• Dopamine agonists linked to higher delta activity at occipital locations and increased frontal gamma power.
• Serotonin antagonists showed elevated slow-wave and alpha power; agonists linked to increased frontal alpha and decreased occipital alpha.
• Norepinephrine antagonists and agonists positively related to delta power, with antagonists showing a broader topographical pattern.
• Histamine antagonists and mixed agents associated with lower delta, theta, and alpha power.
• Acetylcholine antagonists linked to higher delta, theta, and alpha power across locations.

Interpretation:

Modeling psychotropic medication effects on EEG at the neurotransmitter receptor level enhances mechanistic interpretability.

Limitations:

• Study relies on a large but heterogeneous dataset, which may introduce variability in results.
• Potential confounding factors were not accounted for in the analysis.

Conclusion:

The neurotransmitter-centric framework improves upon traditional drug class-based approaches.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.